3 Biotech Stocks That Are Ridiculously Overpriced

·6 min read
3 Biotech Stocks That Are Ridiculously Overpriced

Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a stock. Here's why they picked Cassava Sciences (NASDAQ: SAVA), Ocugen (NASDAQ: OCGN), and Moderna (NASDAQ: MRNA). Prosper Junior Bakiny (Cassava Sciences): Investors have been flocking to this clinical-stage biotech all year long, pushing its share price up by well over 600%.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting